Plozasiran is a medicine for familial chylomicronemia syndrome, a rare inherited condition that causes very high levels of fat (triglycerides) in the blood. It is given as a shot under the skin. It works by telling the liver to make less of a protein that keeps fat in the blood.
Every report comes from a Lived member, sent anonymously.
Have you tried Redemplo (Plozasiran) for Familial Chylomicronemia Syndrome?
Plozasiran, sold as Redemplo, is a prescription injection for adults with familial chylomicronemia syndrome (FCS), a rare inherited condition in which the body cannot properly clear fat from the blood after meals. It is used together with a very low-fat diet to lower triglycerides, the main type of fat carried in the blood. In FCS, triglycerides can reach levels many times higher than normal. A normal fasting level is under 150 mg/dL and 500 mg/dL or more counts as very high; people in the main plozasiran study started at a median of about 2,000 mg/dL, despite diet and other lipid-lowering medicines. At these levels the blood can look milky, and the biggest danger is repeated attacks of acute pancreatitis, a painful and sometimes serious inflammation of the pancreas. Plozasiran is approved in the US only for adults with FCS. Its safety and effectiveness in children have not been established. It is being studied in people with severe high triglycerides from other causes, but that is not an approved use. Another option for FCS is olezarsen (Tryngolza), a monthly injection that targets the same protein in a different way.
Normally, an enzyme called lipoprotein lipase breaks down large fat-carrying particles from food, called chylomicrons, so the fat can be used or stored. In FCS this clearing system works poorly, so chylomicrons build up in the blood. A liver protein called apolipoprotein C-III (apoC-III) slows fat clearance even further. Plozasiran is a small interfering RNA (siRNA), a short strand of genetic material designed to switch off one specific gene message. It is built to be taken up by liver cells, where it destroys the instructions the liver uses to make apoC-III. With much less apoC-III in circulation (about 90% less in the main trial), the body clears triglyceride-rich particles from the blood more effectively. Because the effect lasts for months after each injection, it only needs to be given four times a year.
Plozasiran comes as a single-dose prefilled syringe containing 25 mg, injected under the skin once every 3 months. A clinician shows the patient or a caregiver how to give the first injection, and after that it can be given at home. The usual sites are the front of the thigh or the abdomen; the outer upper arm can be used only when someone else gives the injection. Skin that is bruised, tender, red, hard, scarred or stretch-marked should be avoided, and the solution should be clear and colorless to yellow, not cloudy. If a dose is missed, it is given as soon as possible, and the next one is due 3 months after that injection rather than on the old schedule. Syringes are kept in the refrigerator in their carton, but can stay at room temperature for up to 30 days. The medicine does not replace the diet. People with FCS are still advised to keep fat intake to 20 grams a day or less, because the injection lowers triglycerides without removing the effect of a fatty meal.
The most common side effects in the main trial were higher blood sugar, headache, nausea and reactions where the shot was given, such as pain, redness or swelling. Most people continued treatment; a small number stopped because of high blood sugar or hives. The blood sugar effect is the one most worth watching. Among people who did not already have diabetes, high blood sugar or a diabetes-range result was reported in about 40% of those on plozasiran compared with 20% on placebo, and average HbA1c (a blood test reflecting blood sugar over the past three months) rose slightly. Your care team may check glucose or HbA1c during treatment, and people who already have diabetes may need their treatment reviewed. LDL (low-density lipoprotein) cholesterol, the so-called bad cholesterol, often rose in people with FCS on plozasiran, although it stayed low on average. Small rises in liver enzymes were seen early in treatment and then leveled off.
Plozasiran has no boxed warning and no listed contraindications. Laboratory studies suggest it does not affect the liver enzymes and transport systems behind most drug interactions, so few interactions are expected. Your prescriber and pharmacist should still have a full list of your medicines and supplements, especially any diabetes medicines, since plozasiran can raise blood sugar. There is not enough information to know whether plozasiran is safe during pregnancy. Pregnancy itself raises triglycerides, especially in the third trimester, and in FCS this can trigger pancreatitis, so anyone pregnant or planning a pregnancy should work out a plan with their specialist early. It is not known whether plozasiran passes into breast milk, though it is unlikely to be absorbed by a baby in meaningful amounts. The effects of severe kidney disease or moderate to severe liver disease on plozasiran have not been studied.
Triglycerides fall within the first months. In the main trial, median fasting triglycerides dropped about 80% by 10 months on plozasiran, compared with about 17% on placebo, and the effect held through a year. Fewer people on plozasiran had pancreatitis during that year (2 of 26, versus 5 of 25 on placebo), which is encouraging, but the study was too small to prove that the medicine prevents attacks. Even with a large drop, many people's levels remain above the normal range. Treatment is expected to be long term, because FCS is lifelong and the effect wears off if injections stop. Follow-up usually includes fasting triglyceride tests, blood sugar checks and ongoing support from a dietitian. Pancreatitis can still happen. Sudden, severe pain in the upper abdomen, often with nausea or vomiting, needs urgent medical care right away rather than waiting for the next appointment, and it helps to tell the treating team that you have FCS.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Redemplo (Plozasiran), what you've noticed, or ask the community a question.